Monoclonal antibody · Antagonist of ILT2 (LILRB1) · developed by Agenus
AGEN1571 is a human IgG4 monoclonal antibody that binds to ILT2, an inhibitory immune checkpoint receptor expressed on innate and adaptive immune cells. By blocking ILT2 and preventing its interaction with HLA-G, the antibody relieves immune suppression and promotes anti-tumor immune responses. It is studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05377528 | Phase 1 | Advanced Solid Tumor | Completed | AGEN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumor
Updated Oct 3, 2026. Something wrong or missing? Report it on the AGEN page.
See AGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AGEN catalysts and pipeline →